Immunotherapy for Epstein-Barr Virus-Related Lymphomas
2009
Immunotherapy for Epstein-Barr Virus-Related Lymphomas
Sample size: 114
publication
Evidence: moderate
Author Information
Author(s): Alana A. Kennedy-Nasser, Catherine M. Bollard, Helen E. Heslop
Primary Institution: Center for Cell and Gene Therapy, Baylor College of Medicine
Conclusion
Adoptive immunotherapy offers a potentially curative approach to many patients with EBV-related malignancies.
Supporting Evidence
- Over 95% of individuals are infected with Epstein-Barr virus by adulthood.
- Type III latency tumors express a full array of latent EBV antigens, making them highly immunogenic.
- CD20 monoclonal antibody therapy has shown response rates varying between 55% and 100% in treating EBV-LPD.
Takeaway
This study looks at how doctors can use special treatments to help people with certain cancers caused by a virus called Epstein-Barr. These treatments can help the body fight the cancer better.
Methodology
The study reviews current immunotherapies and future studies aimed at targeting EBV antigen expression in tumors.
Limitations
Responses to treatments vary, and many patients are heavily pretreated, which may affect outcomes.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website